Authors
Jimmy Che-To Lai, Yu Jun Wong, Terry Cheuk-Fung Yip, Anand V Kulkarni
Published in
Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver. Nov 18, 2026. Epub Nov 18, 2026.
Abstract
Autoimmune hepatitis (AIH) is an immune-mediated liver disease in which persistent necroinflammation drives progressive fibrosis, cirrhosis, and ultimately portal hypertension-related decompensation. Effective immunosuppression may halt hepatic inflammation, thereby inducing biochemical (and histological) remission, facilitating regeneration of hepatic function, clinical recompensation, and fibrosis regression. Studies indicate that approximately 19-54% of immunosuppressed patients achieve recompensation. Lower Child-Pugh score, lower immunoglobulin G levels, and a complete biochemical response are associated with higher recompensation rates, whereas advanced-grade hepatic encephalopathy and a higher Model for End-stage Liver Disease score are associated with lower recompensation rates. Recompensation improves prognosis and transplant-free survival compared with non-recompensated AIH patients. However, recompensation should not be equated with resolution of portal hypertension or a reduced risk of hepatocellular carcinoma, which may persist and continue to require surveillance and treatment. CONCLUSION: Recompensation in AIH is possible and confers better clinical outcomes. However, with the definition of aetiological control less well defined, data remain heterogeneous.
PMID:
43052146
Bibliographic data and abstract were imported from PubMed on 19 Nov 2026.
Read full publication at:
Please sign in
to see all details.
Advertisement
Stats
- Recommendations n/a n/a positive of 0 vote(s)
- Views 8
- Comments 0